Eric Rowinsky - Verastem Director
| VSTM Stock | USD 9.98 0.35 3.63% |
Director
Dr. Eric K. Rowinsky, M.D., is Independent Directorof the Company. Dr. Rowinsky is a Class I director who has served as a member of our Board of Directors since May 2017. Dr. Rowinsky was the Executive Director and President of RGenix, Inc. since June 2016. He also has served as the Chief Scientific Officer of Clearpath Development Co. since June 2016. Prior to this, Dr. Rowinsky served as the Head of Research and Development, Chief Medical Officer and Executive Vice President of Stemline Therapeutics, Inc. from February 2011 to January 2016. In 2010, Dr. Rowinsky cofounded Primrose Therapeutics and became its Chief Executive Officer, until it was acquired in 2011. From 2005 to 2010, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly and Company. Previous to that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Centers Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Since 2011, Dr. Rowinsky has served on the boards of directors of Biogen Idec, Inc., Navidea biopharmaceuticals, Inc., and Fortress Biosciences, Inc., and formerly served on the board of directors of BIND Therapeutics, prior to its acquisition by Pfizer since 2017.
| Age | 61 |
| Tenure | 7 years |
| Address | 117 Kendrick Street, Needham, MA, United States, 02494 |
| Phone | 781 292 4200 |
| Web | https://www.verastem.com |
Verastem Management Efficiency
The company has return on total asset (ROA) of (0.4703) % which means that it has lost $0.4703 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3876) %, meaning that it created substantial loss on money invested by shareholders. Verastem's management efficiency ratios could be used to measure how well Verastem manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of May 2024, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Verastem's Other Current Assets are very stable compared to the past year. As of the 2nd of May 2024, Non Current Assets Total is likely to grow to about 11.4 M, while Non Currrent Assets Other are likely to drop about 4.2 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mary Coe | Merck Company | 54 | |
| William Harrison | Merck Company | 70 | |
| Wendell Weeks | Merck Company | 59 | |
| Amy Hanson | LSI Industries | N/A | |
| Thomas Glocer | Merck Company | 61 | |
| Mark Serrianne | LSI Industries | 67 | |
| Carlos Represas | Merck Company | 72 | |
| John Noseworthy | Merck Company | 66 | |
| Thomas Cech | Merck Company | 72 | |
| Dennis Meyer | LSI Industries | 80 | |
| Gary Kreider | LSI Industries | 78 | |
| Kathy Warden | Merck Company | 49 | |
| Peter Wendell | Merck Company | 70 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Christine Seidman | Merck Company | 68 | |
| John Morgan | LSI Industries | 63 | |
| Craig Thompson | Merck Company | 64 | |
| Paul Rothman | Merck Company | 63 | |
| Leslie Brun | Merck Company | 68 | |
| Patricia Russo | Merck Company | 68 | |
| Inge Thulin | Merck Company | 67 | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.47 |
Verastem Leadership Team
Elected by the shareholders, the Verastem's board of directors comprises two types of representatives: Verastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verastem. The board's role is to monitor Verastem's management team and ensure that shareholders' interests are well served. Verastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Gagnon, CFO | ||
| Brian Sullivan, Corporate Development | ||
| MD MSc, Head Strategy | ||
| Louise Phanstiel, Independent Director | ||
| Lisa Buffington, Senior Advocacy | ||
| Lori Kunkel, Clinical and Scientific Advisory Board | ||
| Michelle MD, CoFounder | ||
| Piyush Gupta, CoFounder | ||
| Julie Feder, CFO | ||
| Timothy Barberich, Independent Director | ||
| Eric Rowinsky, Director | ||
| Gregory Berk, Chief Medical Officer | ||
| Lawton Frances, Independent Director | ||
| Joseph Chiapponi, Principal Financial Officer, Principal Accounting Officer, Treasurer | ||
| BPHARM RPh, CEO Director | ||
| Mba MBA, Founder Consultant | ||
| Robert Forrester, President CEO, Director | ||
| Hagop Youssoufian, Head - Hematology and Oncology Development | ||
| Jonathan Pachter, Chief Officer | ||
| Stephen Sherwin, Independent Director | ||
| Paul Friedman, Director | ||
| Richard MBA, Founder Consultant | ||
| Christoph Westphal, Executive Chairman of the Board | ||
| Monica Kleinman, Vice President General Counsel | ||
| Sean Flynn, Gen VP | ||
| Bruce Wendel, Independent Director | ||
| Alison Lawton, Independent Director | ||
| Joe Chiapponi, Principal Financial Officer, Principal Accounting Officer, Treasurer | ||
| John Green, CFO | ||
| Michael Ferraresso, Vice President - Commercial Operations | ||
| Brian Stuglik, Director | ||
| Robert Weinberg, CoFounder Board | ||
| Daniel Calkins, Interim Officer | ||
| Steven Bloom, Chief Strategy Officer | ||
| Michael Kauffman, Independent Director | ||
| Nate Sanburn, Senior Engagement | ||
| Henri Termeer, Lead Independent Director | ||
| Joseph Lobacki, Executive Vice President and Chief Commercial Officer | ||
| Daniel Paterson, CEO President | ||
| Gina Consylman, Director | ||
| Robert MBA, Senior Operations | ||
| Erin Cox, Sr Communications |
Verastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 182.23 M | ||||
| Shares Outstanding | 25.31 M | ||||
| Shares Owned By Insiders | 0.57 % | ||||
| Shares Owned By Institutions | 66.10 % | ||||
| Number Of Shares Shorted | 806.36 K | ||||
| Price To Earning | (3.02) X | ||||
| Price To Book | 4.98 X | ||||
| Price To Sales | 30.96 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Verastem in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Verastem's short interest history, or implied volatility extrapolated from Verastem options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Verastem Stock analysis
When running Verastem's price analysis, check to measure Verastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verastem is operating at the current time. Most of Verastem's value examination focuses on studying past and present price action to predict the probability of Verastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verastem's price. Additionally, you may evaluate how the addition of Verastem to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Verastem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.96) | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.39) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.